Tumor Biology

, Volume 36, Issue 11, pp 8887–8893 | Cite as

Analysis of UHRF1 expression in human ovarian cancer tissues and its regulation in cancer cell growth

  • Feng Yan
  • Xiaoming Wang
  • Lijia Shao
  • Mengyuan Ge
  • Xiaoya Hu
Research Article


Ubiquitin-like with PHD and ring finger domains 1 (UHRF1), known as ICB90 or Np95, has been found to be overexpressed in numerous cancers. In this study, we evaluated the expression level of UHRF1 in ovarian cancer. UHRF1 levels in paired ovarian cancer tissues and adjacent normal tissues from 80 ovarian cancer patients were detected using relative quantitatively PCR and Western blot. Small interfering RNA (siRNA) was introduced in two human ovarian cancer cell lines (SKOV-3 and OVCAR-3) to downregulate the expression of UHRF1. The proliferation of siRNA-treated cells was examined using cell counting kit-8 (CCK-8) assay. The growth of these cells showed a remarkable decrease. Moreover, flow cytometric and Hoechst 33342 assays were used to detect the apoptosis. The diagnostic value of UHRF1 messenger RNA (mRNA) expression in ovarian cancer was estimated by receiver-operator characteristic (ROC) curve. The correlation between UHRF1 mRNA expression and clinicopathologic features of ovarian cancer patients was evaluated by χ 2 test. Our results demonstrated that both UHRF1 mRNA and protein were highly expressed in ovarian cancer tissues and significantly higher than that in adjacent normal tissues. Moreover, the inhibition of UHRF1 may lead to cells to undergo apoptosis. Thus, UHRF1 could act as a new oncogenic factor in ovarian cancer and be a potential molecular target for ovarian cancer gene therapy.


UHRF1 Ovarian cancer Small interfering RNA Tissue Cell apoptosis 



This work was financially supported by the National Natural Science Foundation of China (21475063), Jiangsu Provincial Special Program of Medical Science (BL2013036), and the Grand of Medicine Leading Talents of Jiangsu Health Department (LJ201131)

Conflicts of interest



  1. 1.
    Jemal A, Thomas A, Murray T, Thun M. Cancer statistics [J]. CA Cancer J Clin. 2002;52(1):23–47.CrossRefPubMedGoogle Scholar
  2. 2.
    Breuer EK, Murph MM. The role of proteomics in the diagnosis and treatment of women’s cancers: current trends in technology and future opportunities [J]. Int J Proteomics. 2011; pii: 373584.Google Scholar
  3. 3.
    Bronner C, Achour M, Arima Y, et al. The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future [J]? Pharmacol Ther. 2007;115(3):419–34.CrossRefPubMedGoogle Scholar
  4. 4.
    Yang GL, Zhang LH, Bo JJ, et al. UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer [J]. Med Oncol. 2012;29(2):842–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Lallous N, Legrand P, McEwen AG, et al. The PHD finger of human UHRF1 reveals a new subgroup of unmethylated histone H3 tail readers [J]. PLoS ONE. 2011;6(11), e27599.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Chignola F, Gaetani M, Rebane A, et al. The solutionstructure of the first PHD finger of autoimmune regulator in complex with nonmodified histone H3 tail reveals the antagonistic role of H3R2 methylation [J]. Nucleic Acids Res. 2009;37(9):2951–61.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Chakravarty S, Zeng L, Zhou MM. Structure and site-specific recognition of histone H3 by the PHD finger of human autoimmune regulator [J]. Structure. 2009;17(5):670–9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ramon-Maiques S, Kuo AJ, Carney D, et al. The plant homeodomain finger of RAG2 recognizes histone H3 methylated at both lysine-4 and arginine-2 [J]. Proc Natl Acad Sci U S A. 2007;104(48):18993–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Unoki M, Kelly JD, Neal DE, et al. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer [J]. Br J Cancer. 2009;101(1):98–105.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Sabatino L, Fucci A, Pancione M, et al. UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigeneticsilencing and mediates colorectal cancer progression [J]. Oncogene. 2012;31(49):5061–72.CrossRefPubMedGoogle Scholar
  11. 11.
    Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, et al. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma [J]. Gastroenterology. 2005;129(5):1454–63.CrossRefPubMedGoogle Scholar
  12. 12.
    Babbio F, Pistore C, Curti L, et al. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression [J]. Oncogene. 2012;31(46):4878–87.CrossRefPubMedGoogle Scholar
  13. 13.
    Daskalos A, Oleksiewicz U, Filia A, et al. UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer [J]. Cancer. 2011;117(5):1027–37.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang F, Yang YZ, Shi CZ, et al. UHRF1 promotes cell growth and metastasis through repression of p16ink4a in colorectal cancer [J]. Ann Surg Oncol. 2012;19(8):2753–62.CrossRefPubMedGoogle Scholar
  15. 15.
    Lorenzato M, Caudroy S, Bronner C, et al. Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions [J]? Hum Pathol. 2005;36(10):1101–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Yan F, Tan XY, Geng Y, et al. Inhibition effect of siRNA-downregulated UHRF1 on breast cancer growth [J]. Cancer Biother Radiopharm. 2011;26(2):183–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Jenkins Y, Markovtsov V, Lang W, et al. Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth [J]. Mol Biol Cell. 2005;16(2):5621–9.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Alhosin M, Sharif T, Mousli M, et al. Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties [J]. J Exp Clin Cancer Res. 2011;30:41–50.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Greger V, Debus N, Lohmann D, et al. Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma [J]. Hum Genet. 1994;94(5):491–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer [J]. Nat Rev Genet. 2002;3(6):415–28.PubMedGoogle Scholar
  21. 21.
    Jones PA, Baylin SB. The epigenomics of cancer [J]. Cell. 2007;128(4):683–92.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Baylin SB, Ohm JE. Epigenetic gene silencing in cancer a mechanism for early oncogenic pathway addiction [J]? Nat Rev Cancer. 2006;6(2):107–16.CrossRefPubMedGoogle Scholar
  23. 23.
    Fleuriel C, Touka M, Boulay G, et al. HIC1 (hypermethylated in cancer 1) epigenetic silencing in tumours [J]. Int J Biochem Cell Biol. 2009;41(1):26–33.CrossRefPubMedGoogle Scholar
  24. 24.
    Corn PG, Kuerbitz SJ, van Noesel MM, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukaemia and Burkitt’s lymphoma is associated with 5’CpG island methylation [J]. Cancer Res. 1999;59:3352–6.PubMedGoogle Scholar
  25. 25.
    Kawano S, Miller CW, Gombart AF, et al. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation [J]. Blood. 1999;94(3):1113–20.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Feng Yan
    • 1
    • 2
  • Xiaoming Wang
    • 2
  • Lijia Shao
    • 2
  • Mengyuan Ge
    • 2
  • Xiaoya Hu
    • 1
  1. 1.College of Chemistry and Chemical EngineeringYangzhou UniversityYangzhouChina
  2. 2.Department of clinical LaboratoryNanjing Medical University Cancer Hospital & Jiangsu Cancer HospitalNanjingChina

Personalised recommendations